Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Geleen – page 3

48 clinical trials in Geleen, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Geleen at a glance
48
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

48 trials in Geleen

Open in trial search

Crohn's disease

Not recruiting

Study on the Long-Term Safety and Efficacy of Oral Ozanimod for Patients with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ozanimod
  • Sponsor:Celgene International II S.a.r.l.

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Tolebrutinib
  • Sponsor:Genzyme Corp.

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Plasma cell myeloma

Not recruiting

Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Study Comparing Isatuximab with Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Multiple sclerosis

Not recruiting

Study on Personalized Ocrelizumab Dosing for Patients with Relapsing Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:Amsterdam UMC Stichting

Study on the Effectiveness and Safety of Apalutamide, Abiraterone Acetate, and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Janssen Cilag International

Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Study on the Effectiveness of Paclitaxel, Docetaxel, and Oxaliplatin in Patients with Resectable Gastric Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Malignant melanoma+1

Not recruiting

Study Comparing Ipilimumab and Nivolumab with Standard Nivolumab for Patients with Stage III Melanoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Ipilimumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Study of ibrutinib and venetoclax combination therapy for patients with relapsed or refractory chronic lymphocytic leukemia who have adequate kidney function

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Geleen

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials exploring treatments for various cancer types, including gastric cancer, breast cancer, and lung cancer. Studies focus on innovative therapies and diagnostic approaches.

  • Advanced imaging techniques for cancer staging
  • Novel combination therapies for leukemia
  • Targeted treatments for prostate cancer

Multiple trials investigating personalized treatment approaches and immunotherapy options.

02 Gastrointestinal Disorders

Comprehensive research into inflammatory bowel conditions, with particular focus on Crohn's Disease and Ulcerative Colitis. Studies evaluating long-term treatment effectiveness.

  • Novel oral medications for IBD
  • Long-term disease management
  • Treatment response assessment

Emphasis on developing sustainable treatment options for chronic conditions.

03 Neurological Studies

Advanced research into Multiple Sclerosis treatment and management. Trials focusing on long-term safety and efficacy of innovative therapies.

  • Progressive MS treatments
  • Long-term safety evaluations
  • Disease modification strategies

Investigation of treatment effectiveness in various MS disease courses.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.